for subscribers

Aspen loses cancer drug appeal and must pay €5.2m fine

Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!

Cape Town – Aspen [JSE:APN] has lost its appeal against an Italian Competition Authority ruling in an Italian court, meaning it must now pay a €5.2m (R74m) fine, the South African pharmaceutical company announced on Wednesday.

Aspen said it will engage its advisers and consider the matter further against receipt of those reasons, including Aspen’s automatic right to lodge a further appeal to the Council of State appeal court.

The ruling had not dented Aspen's share price on Wednesday. It was trading 0.64% stronger at R276 a share.

There’s more to this story
Subscribe to News24 and get access to our exclusive journalism and features today.
Subscribe
Already a subscriber? Sign in
ZAR/USD
17.44
(+0.16)
ZAR/GBP
22.74
(+0.41)
ZAR/EUR
20.57
(-0.18)
ZAR/AUD
12.50
(-0.01)
ZAR/JPY
0.16
(+0.59)
Gold
1914.72
(+0.48)
Silver
25.45
(+2.51)
Platinum
928.99
(+0.92)
Brent Crude
44.46
(-1.09)
Palladium
2134.99
(+2.60)
All Share
57417.28
(+0.44)
Top 40
53126.54
(+0.56)
Financial 15
10139.85
(-0.74)
Industrial 25
76210.18
(+0.91)
Resource 10
58992.57
(+0.54)
All JSE data delayed by at least 15 minutes morningstar logo
Company Snapshot
Voting Booth
Do you think it was a good idea for the government to approach the IMF for a $4.3 billion loan to fight Covid-19?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes. We need the money.
11% - 976 votes
It depends on how the funds are used.
74% - 6476 votes
No. We should have gotten the loan elsewhere.
15% - 1344 votes
Vote